6610 Stock Overview
A clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
TWi Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$13.80 |
| 52 Week High | NT$16.40 |
| 52 Week Low | NT$11.15 |
| Beta | 0.61 |
| 1 Month Change | -4.83% |
| 3 Month Change | 2.60% |
| 1 Year Change | 6.98% |
| 3 Year Change | -7.38% |
| 5 Year Change | 58.80% |
| Change since IPO | -79.66% |
Recent News & Updates
Shareholder Returns
| 6610 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -1.4% | -2.8% | 0.5% |
| 1Y | 7.0% | 15.0% | 28.2% |
Return vs Industry: 6610 underperformed the TW Biotechs industry which returned 16% over the past year.
Return vs Market: 6610 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 6610 volatility | |
|---|---|
| 6610 Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6610 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6610's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 21 | Jessica Wu | www.twibiotech.com |
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited.
TWi Biotechnology, Inc. Fundamentals Summary
| 6610 fundamental statistics | |
|---|---|
| Market cap | NT$1.21b |
| Earnings (TTM) | -NT$226.53m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.3x
P/E RatioIs 6610 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6610 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$226.53m |
| Earnings | -NT$226.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6610 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/17 06:13 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TWi Biotechnology, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yu-Ying Yang | KGI Securities Co. Ltd. |